NCT06838208

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Efficacy and Safety of Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in the First-line Treatment of Extensive Small Cell Lung Cancer: a Prospective, Multicenter, Phase II Clinical Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: Anhui Provincial Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer

Conditions

• Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

Type	Name	Description
DRUG	Tislelizumab, Carboplatin /Cisplatin, Etoposide	Induction therapy stage LDRT: lung lesions, 15Gy/5f; Maintenance therapy phase SBRT: The main residual lesions evaluated by the investigators, 30Gy/5f；

Timeline

• Start date: 2025-02-25
• Primary completion: 2027-03-01
• Completion: 2028-04-01
• First posted: 2025-02-20
• Last updated: 2025-09-24

Locations

1 site across 1 country: China